

ICD-10-CM Professional for Hospitals

The complete official guidelines and code set

Codes valid from October 1, 2025
through September 30, 2026

SAMPLE

Contents

How to Use ICD-10-CM Professional for Hospitals 2026	iii
Introduction	iii
What's New for 2026.....	iii
Conversion Table	iii
10 Steps to Correct Coding.....	iii
Official ICD-10-CM Guidelines for Coding and Reporting	iii
Indexes	iii
Index to Diseases and Injuries	iii
Neoplasm Table.....	iii
Table of Drugs and Chemicals	iii
External Causes Index	iv
Index Notations	iv
Tabular List of Diseases	v
Code and Code Descriptions	v
Tabular Notations	v
Official Notations	v
Optum Notations	vi
Icons	vi
Color Bars	vii
Chapter-Level Notations	viii
Illustrations	viii
What's New for 2026	ix
Official Updates	ix
Proprietary Updates	ix
Conversion Table of ICD-10-CM Codes	x
10 Steps to Correct Coding	xii
ICD-10-CM Official Guidelines for Coding and Reporting	Coding Guidelines-1
ICD-10-CM Index to Diseases and Injuries	1
ICD-10-CM Neoplasm Table	339
ICD-10-CM Table of Drugs and Chemicals	358
ICD-10-CM Index to External Causes.....	408
ICD-10-CM Tabular List of Diseases and Injuries	445
Chapter 1. Certain Infectious and Parasitic Diseases (A00–B99), U07.1, U09.9	445
Chapter 2. Neoplasms (C00–D49)	471
Chapter 3. Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism (D50–D89)	513
Chapter 4. Endocrine, Nutritional, and Metabolic Diseases (E00–E89)	527
Chapter 5. Mental, Behavioral and Neurodevelopmental Disorders (F01–F99)	551
Chapter 6. Diseases of the Nervous System (G00–G99)	583
Chapter 7. Diseases of the Eye and Adnexa (H00–H59)	607
Chapter 8. Diseases of the Ear and Mastoid Process (H60–H95)	645
Chapter 9. Diseases of the Circulatory System (I00–I99)	657
Chapter 10. Diseases of the Respiratory System (J00–J99), U07.0	703
Chapter 11. Diseases of the Digestive System (K00–K95)	721
Chapter 12. Diseases of the Skin and Subcutaneous Tissue (L00–L99)	747
Chapter 13. Diseases of the Musculoskeletal System and Connective Tissue (M00–M99)	769
Chapter 14. Diseases of Genitourinary System (N00–N99).....	857
Chapter 15. Pregnancy, Childbirth, and the Puerperium (O00–O9A)	879
Chapter 16. Certain Conditions Originating in the Perinatal Period (P00–P96)	919
Chapter 17. Congenital Malformations, Deformations, and Chromosomal Abnormalities (Q00–Q99)	933
Chapter 18. Symptoms, Signs, and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified (R00–R99)	955
Chapter 19. Injury, Poisoning, and Certain Other Consequences of External Causes (S00–T88)	977
Chapter 20. External Causes of Morbidity (V00–Y99)	1193
Chapter 21. Factors Influencing Health Status and Contact with Health Services (Z00–Z99)	1259
Chapter 22. Codes for Special Purposes (U00–U85).....	1299
Illustrations.....	Illustrations-1
Chapter 3. Diseases of the Blood and Blood-forming Organs and Certain Disorders Involving the Immune Mechanism (D50–D89)	Illustrations-1
Red Blood Cells	Illustrations-1
White Blood Cell	Illustrations-1
Platelet	Illustrations-2
Coagulation	Illustrations-2
Spleen Anatomical Location and External Structures	Illustrations-3
Spleen Interior Structures	Illustrations-3
Chapter 4. Endocrine, Nutritional, and Metabolic Diseases (E00–E89)	Illustrations-4
Endocrine System	Illustrations-4
Thyroid	Illustrations-5
Thyroid and Parathyroid Glands	Illustrations-5
Pancreas	Illustrations-6
Anatomy of the Adrenal Gland	Illustrations-6
Structure of an Ovary	Illustrations-7
Testis and Associated Structures	Illustrations-7
Thymus	Illustrations-8
Chapter 6. Diseases of the Nervous System (G00–G99) ..	Illustrations-9
Brain	Illustrations-9
Cranial Nerves	Illustrations-9
Peripheral Nervous System	Illustrations-10
Spinal Cord and Spinal Nerves	Illustrations-11
Nerve Cell	Illustrations-12
Trigeminal and Facial Nerve Branches	Illustrations-12
Chapter 7. Diseases of the Eye and Adnexa (H00–H59)	Illustrations-13
Eye	Illustrations-13
Posterior Pole of Globe/Flow of Aqueous Humor	Illustrations-13
Lacrimal System	Illustrations-14
Eye Musculature	Illustrations-14
Eyelid Structures	Illustrations-14
Chapter 8. Diseases of the Ear and Mastoid Process (H60–H95)	Illustrations-15
Ear Anatomy	Illustrations-15
Chapter 9. Diseases of the Circulatory System (I00–I99)	Illustrations-16
Anatomy of the Heart	Illustrations-16
Heart Cross Section	Illustrations-16
Heart Valves	Illustrations-17
Heart Conduction System	Illustrations-17

Coronary Arteries	Illustrations–18	Bones and Joints	Illustrations–32
Arteries	Illustrations–19	Shoulder Anterior View	Illustrations–33
Veins	Illustrations–20	Shoulder Posterior View	Illustrations–33
Internal Carotid and Vertebral		Elbow Anterior View	Illustrations–33
Arteries and Branches	Illustrations–21	Elbow Posterior View	Illustrations–33
External Carotid Artery and Branches	Illustrations–21	Hand	Illustrations–33
Branches of Abdominal Aorta	Illustrations–22	Hip Anterior View	Illustrations–34
Portal Venous Circulation	Illustrations–22	Hip Posterior View	Illustrations–34
Lymphatic System	Illustrations–23	Knee Anterior View	Illustrations–34
Axillary Lymph Nodes	Illustrations–24	Knee Posterior View	Illustrations–34
Lymphatic System of Head		Foot	Illustrations–34
and Neck	Illustrations–24	Muscles.....	Illustrations–35
Lymphatic Capillaries	Illustrations–25		
Lymphatic Drainage	Illustrations–25	Chapter 14. Diseases of Genitourinary	
Chapter 10. Diseases of the Respiratory		System (N00–N99)	Illustrations–36
System (J00–J99), U07.0	Illustrations–26	Urinary System	Illustrations–36
Respiratory System	Illustrations–26	Male Genitourinary System	Illustrations–37
Upper Respiratory System	Illustrations–27	Female Internal Genitalia	Illustrations–37
Lower Respiratory System	Illustrations–27	Female Genitourinary Tract Lateral	
Paranasal Sinuses	Illustrations–27	View	Illustrations–37
Lung Segments	Illustrations–28	Chapter 15. Pregnancy, Childbirth, and the	
Alveoli	Illustrations–28	Puerperium (O00–O9A)	Illustrations–38
Chapter 11. Diseases of the Digestive System		Term Pregnancy – Single Gestation	Illustrations–38
(K00–K95)	Illustrations–29	Twin Gestation–Dichorionic–	
Digestive System	Illustrations–29	Diamniotic (DI-DI)	Illustrations–38
Omentum and Mesentery	Illustrations–30	Twin Gestation–Monochorionic–	
Peritoneum and Retroperitoneum	Illustrations–30	Diamniotic (MO-DI)	Illustrations–39
Chapter 12. Diseases of the Skin and Subcutaneous		Twin Gestation–Monochorionic–	
Tissue (L00–L99)	Illustrations–31	Monoamniotic (MO-MO)	Illustrations–39
Nail Anatomy	Illustrations–31	Chapter 19. Injury, Poisoning, and Certain Other	
Skin and Subcutaneous Tissue	Illustrations–31	Consequences of External Causes	
Chapter 13. Diseases of the Musculoskeletal System		(S00–T88)	Illustrations–40
and Connective Tissue (M00–M99)	Illustrations–32	Types of Fractures	Illustrations–40
		Salter-Harris Fracture Types	Illustrations–40

A Adult Age: 15-124

These diagnoses are intended for patients between the age of 15 and 124 years.

R54 Age-related physical debility A

- Frailty
- Old age
- Senescence
- Senile asthenia
- Senile debility

EXCLUDES1 *age-related cognitive decline (R41.81)*
sarcopenia (M62.84)
senile psychosis (F03.-)
senility NOS (R41.81)

Sex Edits

Effective October 1, 2024, the Medicare Code Editor (MCE), a program used to detect and report errors in coding claims data, has deactivated the sex conflict edit. There is no longer a female or male edit restriction for ICD-10-CM codes.

H1 - H14 Hospital Acquired Condition (HAC)

These icons identify codes that are high-cost and/or high-volume (CC or MCC) that when assigned as a secondary diagnosis result in assignment of a case to a higher-paying MS-DRG. The condition or diagnosis represented by these codes is considered reasonably preventable through the application of evidence-based guidelines. If the condition is not present on admission (meaning it developed during the hospital admission), the case will not group to the higher-paying MS-DRG based solely upon the reporting of the HAC code. Many of these HACs are conditional and are based on reporting the specific diagnosis code(s) in combination with certain procedure codes.

Note: Hospital-acquired conditions do not impact MS-LTC-DRG assignment.

N15.1 Renal and perinephric abscess MCC H6

CC Condition

This icon identifies a complication or comorbidity diagnosis that may affect DRG assignment. A complication or comorbidity diagnosis, CC condition, is defined as a significant acute disease, a significant acute manifestation of a chronic disease, an advanced or end-stage chronic disease, or a chronic disease associated with systemic physiological decompensation and debility that have consistently greater impact on hospital resources.

G90.59 Complex regional pain syndrome I of other specified site CC

MCC Condition

This icon identifies a major complication or comorbidity diagnosis that may affect DRG assignment. An MCC condition meets the same criteria as a CC condition but is associated with a higher acuity level and hospital resource consumption is expected to be higher than that for a CC condition. There are fewer conditions that meet the criteria as an MCC than those for a CC condition.

J04.11 Acute tracheitis with obstruction MCC

Note: The assignment of an MS-DRG or MS-LTC-DRG often depends on the presence or absence of a secondary diagnosis code that is designated as an MCC or CC. However, in some instances the MCC or CC designation for that secondary diagnosis code is negated due to its relationship with the principal diagnosis; this is referred to as CC exclusion. The ICD-10 MS-DRG Definitions Manual included with the IPPS final rule provides a list of all principal diagnosis codes that would render ineffective the MCC/CC designation for a particular ICD-10-CM code when used as a secondary diagnosis. Optum has provided this CC exclusion list in an easily searchable data file, which can be accessed at the following:

<https://www.optumcoding.com/ProductUpdates/>
 Title: "2025 ICD-10-CM for Hospitals CC Excludes Data File"
 Password: HOSPITAL25

UNS Unspecified Site

This icon identifies codes that are considered an MCC or CC but lack specificity in regard to their anatomical location. The medical record documentation should be reviewed carefully, to ensure that no other code within the same category or subcategory can be assigned for greater specificity.

G81.00 Flaccid hemiplegia affecting unspecified side CC UNS HCC

UPD Unacceptable Principal Diagnosis

This icon identifies codes that should not be assigned as principal diagnosis for *inpatient* admissions. Codes with an unacceptable principal diagnosis edit are considered supplementary — describing circumstances that influence an individual’s health status or an additional code — identifying conditions that are not specific manifestations but may be due to an underlying cause.

T48.5X5 Adverse effect of other anti-common-cold drugs UPD PE

HIV HIV-related Condition

This icon identifies codes that are considered a major HIV-related diagnosis. When the condition is coded in combination with a diagnosis of human immunodeficiency virus (HIV), code B20, the case will move from MS-DRG/MS-LTC-DRG 977 to MS-DRGs/MS-LTC-DRGs 974-976.

G96.9 Disorder of central nervous system, unspecified HIV

PE Present on Admission Exempt

This icon identifies codes that do not require a present on admission (POA) indicator. These codes are considered exempt because they do not represent a current disease or injury or describe conditions that are always present on admission

B90.1 Sequelae of genitourinary tuberculosis PE

HCC CMS-HCC Condition

This icon identifies codes that are included in the CMS-HCC risk-adjustment model.

P29.0 Neonatal cardiac failure HCC
Code also associated underlying condition

Color Bars

Manifestation Code

Codes defined as manifestation codes appear in italic type, with a blue color bar over the code description. A manifestation cannot be reported as a first-listed code; it is sequenced as a secondary diagnosis with the underlying disease code listed first.

G32.89 Other specified degenerative disorders of nervous system in diseases classified elsewhere HCC
Degenerative encephalopathy in diseases classified elsewhere

Questionable Admission Diagnoses

Questionable admission diagnoses will appear with a yellow color bar over the code description. These codes, although not unacceptable as a PDX, may be considered a “questionable admission” when used as PDX in an acute care hospital.

E66.09 Other obesity due to excess calories HCC

ICD-10-CM Index to Diseases and Injuries

A

Aarskog's syndrome Q87.19

Abandonment — see Maltreatment

Abasia (-astasia) (hysterical) F44.4

Abderhalden-Kaufmann-Lignac syndrome (cystinosis) E72.04

Abdomen, abdominal — see also condition

acute R10.0

angina K55.1

muscle deficiency syndrome Q79.4

Abdominalgia — see Pain, abdominal

Abduction contracture, hip or other joint — see Contraction, joint

Aberrant (congenital) — see also Malposition, congenital

adrenal gland Q89.1

artery (peripheral) Q27.8

basilar NEC Q28.1

cerebral Q28.3

coronary Q24.5

digestive system Q27.8

eye Q15.8

lower limb Q27.8

precerebral Q28.1

pulmonary Q25.79

renal Q27.2

retina Q14.1

specified site NEC Q27.8

subclavian Q27.8

upper limb Q27.8

vertebral Q28.1

breast Q83.8

endocrine gland NEC Q89.2

hepatic duct Q44.5

pancreas Q45.3

parathyroid gland Q89.2

pituitary gland Q89.2

sebaceous glands, mucous membrane, mouth, congenital Q38.6

spleen Q89.09

subclavian artery Q27.8

thymus (gland) Q89.2

thyroid gland Q89.2

vein (peripheral) NEC Q27.8

cerebral Q28.3

digestive system Q27.8

lower limb Q27.8

precerebral Q28.1

specified site NEC Q27.8

upper limb Q27.8

Aberration

distantal — see Disturbance, visual

mental F99

Abetalipoproteinemia E78.6

Abiotrophy R68.89

Ablatio, ablation

retinae — see Detachment, retina

Ablepharia, ablepharon Q10.3

Abnormal, abnormality, abnormalities — see also

Anomaly

acid-base balance (mixed) E87.4

albumin R77.0

alphafetoprotein R77.2

alveolar ridge K08.9

anatomical relationship Q89.9

apertures, congenital, diaphragm Q79.1

atrial septal, specified NEC Q21.19

auditory perception H93.29-

diplacusis — see Diplacusis

hyperacusis — see Hyperacusis

recruitment — see Recruitment, auditory

threshold shift — see Shift, auditory threshold

autosomes Q99.9

fragile site Q95.5

basal metabolic rate R94.8

biosynthesis, testicular androgen E29.1

bleeding time R79.1

blood amino-acid level R79.83

blood level (of)

cobalt R79.0

copper R79.0

iron R79.0

Abnormal, abnormality, abnormalities — continued

blood level — continued

lithium R78.89

magnesium R79.0

mineral NEC R79.0

zinc R79.0

blood pressure

elevated R03.0

low reading (nonspecific) R03.1

blood sugar R73.09

blood-gas level R79.81

bowel sounds R19.15

absent R19.11

hyperactive R19.12

brain scan R94.02

breathing R06.9

caloric test R94.138

cerebrospinal fluid R83.9

cytology R83.6

drug level R83.2

enzyme level R83.0

hormones R83.1

immunology R83.4

microbiology R83.5

nonmedicinal level R83.3

specified type NEC R83.8

chemistry, blood R79.9

C-reactive protein R79.82

drugs — see Findings, abnormal, in blood

gas level R79.81

minerals R79.0

pancytopenia D61.818

PTT R79.1

specified NEC R79.89

toxins — see Findings, abnormal, in blood

chest sounds (friction) (rales) R09.89

chromosome, chromosomal Q99.9

with more than three X chromosomes, female Q97.1

analysis result R89.8

bronchial washings R84.8

cerebrospinal fluid R83.8

cervix uteri NEC R87.89

nasal secretions R84.8

nipple discharge R89.8

peritoneal fluid R85.89

pleural fluid R84.8

prostatic secretions R86.8

saliva R85.89

semenal fluid R86.8

sputum R84.8

synovial fluid R89.8

throat scrapings R84.8

vagina R87.89

vulva R87.89

wound secretions R89.8

dicentric replacement Q93.2

ring replacement Q93.2

sex Q99.8

female phenotype Q97.9

specified NEC Q97.8

male phenotype Q98.9

specified NEC Q98.8

structural male Q98.6

specified NEC Q99.8

clinical findings NEC R68.89

coagulation D68.9

newborn, transient P61.6

profile R79.1

time R79.1

communication — see Fistula

conjunctiva, vascular H11.41-

coronary artery Q24.5

cortisol-binding globulin E27.8

course, eustachian tube Q17.8

creatinine clearance R94.4

cytology

anus R85.619

atypical squamous cells cannot exclude high grade

squamous intraepithelial lesion (ASC-H)

R85.611

atypical squamous cells of undetermined signifi-

cance (ASC-US) R85.610

cytologic evidence of malignancy R85.614

Abnormal, abnormality, abnormalities — continued

cytology — continued

anus — continued

high grade squamous intraepithelial lesion (HGSIL)

R85.613

human papillomavirus (HPV) DNA test

high risk positive R85.81

low risk positive R85.82

inadequate smear R85.615

low grade squamous intraepithelial lesion (LGSIL)

R85.612

satisfactory anal smear but lacking transformation

zone R85.616

specified NEC R85.618

unsatisfactory smear R85.615

female genital organs — see Abnormal, Papanicolaou

(smear)

dark adaptation curve H53.61

dentofacial NEC — see Anomaly, dentofacial

development, developmental Q89.9

central nervous system Q07.9

diagnostic imaging

abdomen, abdominal region NEC R93.5

biliary tract R93.2

bladder R93.41

breast R92.8

central nervous system NEC R90.89

cerebrovascular NEC R90.89

coronary circulation R93.1

digestive tract NEC R93.3

gastrointestinal (tract) R93.3

genitourinary organs R93.89

head R93.0

heart R93.1

intrathoracic organ NEC R93.89

kidney R93.42-

limbs R93.6

liver R93.2

lung (field) R91.8

musculoskeletal system NEC R93.7

renal pelvis R93.41

retroperitoneum R93.5

site specified NEC R93.89

skin and subcutaneous tissue R93.89

skull R93.0

testis R93.81-

ureter R93.41

urinary organs specified NEC R93.49

direction, teeth, fully erupted M26.30

ear ossicles, acquired NEC H74.39-

ankylosis — see Ankylosis, ear ossicles

discontinuity — see Discontinuity, ossicles, ear

partial loss — see Loss, ossicles, ear (partial)

Ebstein Q22.5

echocardiogram R93.1

echoencephalogram R90.81

echogram — see Abnormal, diagnostic imaging

electrocardiogram [ECG] [EKG] R94.31

electroencephalogram [EEG] R94.01

electrolyte — see Imbalance, electrolyte

electromyogram [EMG] R94.131

electro-oculogram [EOG] R94.110

electrophysiological intracardiac studies R94.39

electroretinogram [ERG] R94.111

erythrocytes

congenital, with perinatal jaundice D58.9

feces (color) (contents) (mucus) R19.5

finding — see Findings, abnormal, without diagnosis

fluid

amniotic — see Abnormal, specimen, specified

cerebrospinal — see Abnormal, cerebrospinal fluid

peritoneal — see Abnormal, specimen, digestive or-

gans

pleural — see Abnormal, specimen, respiratory organs

synovial — see Abnormal, specimen, specified

thorax (bronchial washings) (pleural fluid) — see Ab-

normal, specimen, respiratory organs

vaginal — see Abnormal, specimen, female genital

organs

form

teeth K00.2

uterus — see Anomaly, uterus

	Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior		Malignant Primary	Malignant Secondary	Ca in situ	Benign	Uncertain Behavior	Unspecified Behavior
Neoplasm, neoplastic							Neoplasm, neoplastic						
— <i>continued</i>							— <i>continued</i>						
brain — <i>continued</i>							bronchus — <i>continued</i>						
basal ganglia	C71.0	C79.31	—	D33.0	D43.0	D49.6	main	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
cerebellopontine angle	C71.6	C79.31	—	D33.1	D43.1	D49.6	middle lobe of lung	C34.2	C78.0-✓	D02.21	D14.31	D38.1	D49.1
cerebellum NOS	C71.6	C79.31	—	D33.1	D43.1	D49.6	overlapping lesion	C34.8-✓	—	—	—	—	—
cerebrum	C71.0	C79.31	—	D33.0	D43.0	D49.6	upper lobe of lung	C34.1-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
choroid plexus	C71.7	C79.31	—	D33.1	D43.1	D49.6	brow	C44.309	C79.2	D04.39	D23.39	D48.5	D49.2
corpus callosum	C71.8	C79.31	—	D33.2	D43.2	D49.6	basal cell carcinoma specified type NEC	C44.319	—	—	—	—	—
corpus striatum	C71.0	C79.31	—	D33.0	D43.0	D49.6	squamous cell carcinoma	C44.329	—	—	—	—	—
cortex (cerebral)	C71.0	C79.31	—	D33.0	D43.0	D49.6	buccal (cavity)	C06.9	C79.89	D00.00	D10.39	D37.09	D49.0
frontal lobe	C71.1	C79.31	—	D33.0	D43.0	D49.6	commissure	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
globus pallidus	C71.0	C79.31	—	D33.0	D43.0	D49.6	groove (lower)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
hippocampus	C71.2	C79.31	—	D33.0	D43.0	D49.6	(upper)	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
hypothalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6	mucosa	C06.0	C79.89	D00.02	D10.39	D37.09	D49.0
internal capsule	C71.0	C79.31	—	D33.0	D43.0	D49.6	sulcus (lower)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
medulla							(upper)	C06.1	C79.89	D00.02	D10.39	D37.09	D49.0
oblongata	C71.7	C79.31	—	D33.1	D43.1	D49.6	bulbourethral gland	C68.0	C79.19	D09.19	D30.4	D41.3	D49.59
meninges	C70.0	C79.32	—	D32.0	D42.0	D49.7	bursa — <i>see</i> Neoplasm, connective tissue						
midbrain	C71.7	C79.31	—	D33.1	D43.1	D49.6	buttock NEC	C76.3	C79.89	D04.5	D36.7	D48.7	D49.89
occipital lobe	C71.4	C79.31	—	D33.0	D43.0	D49.6	calves	C76.5-✓	C79.89	D04.7-✓	D36.7	D48.7	D49.89
overlapping lesion	C71.8	C79.31	—	—	—	—	calvarium	C41.0	C79.51	—	D16.4	D48.0	D49.2
parietal lobe	C71.3	C79.31	—	D33.0	D43.0	D49.6	calyx, renal canal	C65.1-✓	C79.0-✓	D09.19	D30.1-✓	D41.1-✓	D49.51-✓
peduncle	C71.7	C79.31	—	D33.1	D43.1	D49.6	anal	C21.1	C78.5	D01.3	D12.9	D37.8	D49.0
pons	C71.7	C79.31	—	D33.1	D43.1	D49.6	auditory (external) — <i>see also</i> Neoplasm, skin, ear	C44.20-✓	C79.2	D04.2-✓	D23.2-✓	D48.5	D49.2
stem	C71.7	C79.31	—	D33.1	D43.1	D49.6	auricular (external) — <i>see also</i> Neoplasm, skin, ear	C44.20-✓	C79.2	D04.2-✓	D23.2-✓	D48.5	D49.2
tapetum	C71.8	C79.31	—	D33.2	D43.2	D49.6	canaliculi, biliary (biliferi)	C44.20-✓	C79.2	D04.2-✓	D23.2-✓	D48.5	D49.2
temporal lobe	C71.2	C79.31	—	D33.0	D43.0	D49.6	(intrahepatic)	C22.1	C78.7	D01.5	D13.4	D37.6	D49.0
thalamus	C71.0	C79.31	—	D33.0	D43.0	D49.6	canthus (eye) (inner)	C44.10-✓	C79.2	D04.1-✓	D23.1-✓	D48.5	D49.2
uncus	C71.2	C79.31	—	D33.0	D43.0	D49.6	basal cell carcinoma	C44.11-✓	—	—	—	—	—
ventricle (floor)	C71.5	C79.31	—	D33.0	D43.0	D49.6	sebaceous cell carcinoma	C44.13-✓	—	—	—	—	—
fourth	C71.7	C79.31	—	D33.1	D43.1	D49.6	specified type NEC	C44.19-✓	—	—	—	—	—
branchial (left) (cyst) (vestiges)	C10.4	C79.89	D00.08	D10.5	D37.05	D49.0	squamous cell carcinoma	C44.12-✓	—	—	—	—	—
breast (connective tissue) (glandular tissue) (soft parts)	C50.9-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	capillary — <i>see</i> Neoplasm, connective tissue	C18.0	C78.5	D01.0	D12.0	D37.4	D49.0
areola	C50.0-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	caput coli	C18.0	C78.5	D01.0	D12.0	D37.4	D49.0
axillary tail	C50.6-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	carcinoid — <i>see</i> Tumor, carcinoid	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
central portion	C50.1-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	cardia (gastric)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
inner	C50.8-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	cardiac orifice (stomach)	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
lower	C50.8-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	cardio-esophageal junction	C16.0	C78.89	D00.2	D13.1	D37.1	D49.0
lower-inner quadrant	C50.3-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	cardio-esophagus carina (bronchus)	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1
lower-outer quadrant	C50.5-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	carotid (artery)	C49.0	C79.89	—	D21.0	D48.1-✓	D49.2
mastectomy site (skin) — <i>see also</i> Neoplasm, breast, skin	C44.501	C79.2	—	—	—	—	body	C75.4	C79.89	—	D35.5	D44.6	D49.7
specified as breast tissue	C50.8-✓	C79.81	—	—	—	—	carpus (any bone)	C40.1-✓	C79.51	—	D16.1-✓	—	—
midline	C50.8-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	cartilage (articular) (joint) NEC — <i>see also</i> Neoplasm, bone	C41.9	C79.51	—	D16.9	D48.0	D49.2
nipple	C50.0-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	arytenoid	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
outer	C50.8-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	auricular	C49.0	C79.89	—	D21.0	D48.1-✓	D49.2
overlapping lesion	C50.8-✓	—	—	—	—	—	bronchi	C34.0-✓	C78.39	—	D14.3-✓	D38.1	D49.1
skin	C44.501	C79.2	D04.5	D23.5	D48.5	D49.2	costal	C41.3	C79.51	—	D16.7	D48.0	D49.2
basal cell carcinoma	C44.511	—	—	—	—	—	cricoid	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
specified type NEC	C44.591	—	—	—	—	—	cuneiform	C32.3	C78.39	D02.0	D14.1	D38.0	D49.1
squamous cell carcinoma	C44.521	—	—	—	—	—	ear (external)	C49.0	C79.89	—	D21.0	D48.1-✓	D49.2
tail (axillary)	C50.6-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	ensiform	C41.3	C79.51	—	D16.7	D48.0	D49.2
upper	C50.8-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3	epiglottis	C32.1	C78.39	D02.0	D14.1	D38.0	D49.1
upper-inner quadrant	C50.2-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3							
upper-outer quadrant	C50.4-✓	C79.81	D05.1-✓	D24.1-✓	D48.6-✓	D49.3							
broad ligament	C57.1-✓	C79.82	D07.39	D28.2	D39.8	D49.59							
bronchiogenic, bronchogenic (lung)	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
bronchiole	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
bronchus	C34.9-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
carina	C34.0-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							
lower lobe of lung	C34.3-✓	C78.0-✓	D02.2-✓	D14.3-✓	D38.1	D49.1							

Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under-dosing	Substance	Poisoning, Accidental (unintentional)	Poisoning, Intentional Self-harm	Poisoning, Assault	Poisoning, Undetermined	Adverse Effect	Under-dosing
Androstalolone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthilimine	T37.4X1	T37.4X2	T37.4X3	T37.4X4	T37.4X5	T37.4X6
Androstanolone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthrakin	T49.4X1	T49.4X2	T49.4X3	T49.4X4	T49.4X5	T49.4X6
Androsterone	T38.7X1	T38.7X2	T38.7X3	T38.7X4	T38.7X5	T38.7X6	Anthracycline	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
Anemone pulsatilla	T62.2X1	T62.2X2	T62.2X3	T62.2X4	—	—	Antiadrenergic NEC	T44.8X1	T44.8X2	T44.8X3	T44.8X4	T44.8X5	T44.8X6
Anesthesia							Antiallergic NEC	T45.0X1	T45.0X2	T45.0X3	T45.0X4	T45.0X5	T45.0X6
caudal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiandrogen NEC	T38.6X1	T38.6X2	T38.6X3	T38.6X4	T38.6X5	T38.6X6
endotracheal	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	Anti-anemic (drug) (preparation)	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6
epidural	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antianxiety drug NEC	T43.501	T43.502	T43.503	T43.504	T43.505	T43.506
inhalation	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	Antiaris toxicaria	T65.891	T65.892	T65.893	T65.894	—	—
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiarteriosclerotic drug	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
mucosal	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antiasthmatic drug NEC	T48.6X1	T48.6X2	T48.6X3	T48.6X4	T48.6X5	T48.6X6
muscle relaxation	T48.1X1	T48.1X2	T48.1X3	T48.1X4	T48.1X5	T48.1X6	Antibiotic Otic Suspension (Solution)*	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
nerve blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Antibiotic	T36.91	T36.92	T36.93	T36.94	T36.95	T36.96
plexus blocking	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	aminoglycoside	T36.5X1	T36.5X2	T36.5X3	T36.5X4	T36.5X5	T36.5X6
potentiated	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	anticancer	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	antifungal	T36.7X1	T36.7X2	T36.7X3	T36.7X4	T36.7X5	T36.7X6
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	antimycobacterial	T36.5X1	T36.5X2	T36.5X3	T36.5X4	T36.5X5	T36.5X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	antineoplastic	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
regional	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	b-lactam NEC	T36.1X1	T36.1X2	T36.1X3	T36.1X4	T36.1X5	T36.1X6
surface	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	cephalosporin (group)	T36.1X1	T36.1X2	T36.1X3	T36.1X4	T36.1X5	T36.1X6
Anesthetic NEC — see also Anesthesia	T41.41	T41.42	T41.43	T41.44	T41.45	T41.46	chloramphenicol (group)	T36.2X1	T36.2X2	T36.2X3	T36.2X4	T36.2X5	T36.2X6
with muscle relaxant	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	ENT	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	eye	T49.5X1	T49.5X2	T49.5X3	T49.5X4	T49.5X5	T49.5X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	fungicidal (local)	T49.0X1	T49.0X2	T49.0X3	T49.0X4	T49.0X5	T49.0X6
gaseous NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	intestinal	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
general NEC	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	local	T49.0X1	T49.0X2	T49.0X3	T49.0X4	T49.0X5	T49.0X6
halogenated hydrocarbon derivatives NEC	T41.0X1	T41.0X2	T41.0X3	T41.0X4	T41.0X5	T41.0X6	macrolides	T36.3X1	T36.3X2	T36.3X3	T36.3X4	T36.3X5	T36.3X6
infiltration NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	polypeptide specified NEC	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
intravenous NEC	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6	tetracycline (group)	T36.8X1	T36.8X2	T36.8X3	T36.8X4	T36.8X5	T36.8X6
local NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	throat	T49.6X1	T49.6X2	T49.6X3	T49.6X4	T49.6X5	T49.6X6
rectal	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	Anticancer agents NEC	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6
general	T41.201	T41.202	T41.203	T41.204	T41.205	T41.206	Anticholesterolemic drug NEC	T46.6X1	T46.6X2	T46.6X3	T46.6X4	T46.6X5	T46.6X6
local	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Anticholinergic NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6
regional NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	Anticholinesterase	T44.0X1	T44.0X2	T44.0X3	T44.0X4	T44.0X5	T44.0X6
spinal NEC	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	organophosphorus insecticide	T44.0X1	T44.0X2	T44.0X3	T44.0X4	T44.0X5	T44.0X6
thiobarbiturate	T41.1X1	T41.1X2	T41.1X3	T41.1X4	T41.1X5	T41.1X6	nerve gas	T60.0X1	T60.0X2	T60.0X3	—	—	—
topical	T41.3X1	T41.3X2	T41.3X3	T41.3X4	T41.3X5	T41.3X6	reversible	T44.0X1	T44.0X2	T44.0X3	T44.0X4	T44.0X5	T44.0X6
Aneurine	T45.2X1	T45.2X2	T45.2X3	T45.2X4	T45.2X5	T45.2X6	ophthalmological	T49.5X1	T49.5X2	T49.5X3	T49.5X4	T49.5X5	T49.5X6
Angeliq*	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6	Anticoagulant NEC	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516
Angio-Conray	T50.8X1	T50.8X2	T50.8X3	T50.8X4	T50.8X5	T50.8X6	Antagonist	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6
Angiotensin	T44.5X1	T44.5X2	T44.5X3	T44.5X4	T44.5X5	T44.5X6	Anti-common-cold drug NEC	T48.5X1	T48.5X2	T48.5X3	T48.5X4	T48.5X5	T48.5X6
Angiotensinamide	T44.991	T44.992	T44.993	T44.994	T44.995	T44.996	Anticonvulsant	T42.71	T42.72	T42.73	T42.74	T42.75	T42.76
Anhydrohydroxy-progesterone	T38.5X1	T38.5X2	T38.5X3	T38.5X4	T38.5X5	T38.5X6	barbiturate	T42.3X1	T42.3X2	T42.3X3	T42.3X4	T42.3X5	T42.3X6
Anhydron	T50.2X1	T50.2X2	T50.2X3	T50.2X4	T50.2X5	T50.2X6	combination (with barbiturate)	T42.3X1	T42.3X2	T42.3X3	T42.3X4	T42.3X5	T42.3X6
Anileridine	T40.491	T40.492	T40.493	T40.494	T40.495	T40.496	hydantoin	T42.0X1	T42.0X2	T42.0X3	T42.0X4	T42.0X5	T42.0X6
Aniline (dye) (liquid) analgesic derivatives, therapeutic NEC	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—	hypnotic NEC	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
vapor	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—	oxazolinedione	T42.2X1	T42.2X2	T42.2X3	T42.2X4	T42.2X5	T42.2X6
Anisocorpine	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	pyrimidinedione specified NEC	T42.6X1	T42.6X2	T42.6X3	T42.6X4	T42.6X5	T42.6X6
Anise oil	T47.5X1	T47.5X2	T47.5X3	T47.5X4	T47.5X5	T47.5X6	succinimide	T42.2X1	T42.2X2	T42.2X3	T42.2X4	T42.2X5	T42.2X6
Anisidine	T65.3X1	T65.3X2	T65.3X3	T65.3X4	—	—	Antidepressant	T43.201	T43.202	T43.203	T43.204	T43.205	T43.206
Anisindione	T45.511	T45.512	T45.513	T45.514	T45.515	T45.516	monoamine oxidase inhibitor	T43.1X1	T43.1X2	T43.1X3	T43.1X4	T43.1X5	T43.1X6
Anisotropine methyl-bromide	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	selective serotonin norepinephrine reuptake inhibitor	T43.211	T43.212	T43.213	T43.214	T43.215	T43.216
Anistreplase	T45.611	T45.612	T45.613	T45.614	T45.615	T45.616	selective serotonin reuptake inhibitor	T43.221	T43.222	T43.223	T43.224	T43.225	T43.226
Anorexiant (central)	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6	specified NEC	T43.291	T43.292	T43.293	T43.294	T43.295	T43.296
Anorexic agents	T50.5X1	T50.5X2	T50.5X3	T50.5X4	T50.5X5	T50.5X6	tetracycline	T43.021	T43.022	T43.023	T43.024	T43.025	T43.026
Ansaid*	T39.311	T39.312	T39.313	T39.314	T39.315	T39.316	triazolopyridine	T43.211	T43.212	T43.213	T43.214	T43.215	T43.216
Ansamycin	T36.6X1	T36.6X2	T36.6X3	T36.6X4	T36.6X5	T36.6X6	tricyclic	T43.011	T43.012	T43.013	T43.014	T43.015	T43.016
Ant (bite) (sting)	T63.421	T63.422	T63.423	T63.424	—	—	Antidiabetic NEC	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
Antabuse	T50.6X1	T50.6X2	T50.6X3	T50.6X4	T50.6X5	T50.6X6	biguanide and sulfonyl combined	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
Antacid NEC	T47.1X1	T47.1X2	T47.1X3	T47.1X4	T47.1X5	T47.1X6	combined	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
Antagonist							sulfonylurea	T38.3X1	T38.3X2	T38.3X3	T38.3X4	T38.3X5	T38.3X6
Aldosterone	T50.0X1	T50.0X2	T50.0X3	T50.0X4	T50.0X5	T50.0X6	Antidiarrheal drug NEC	T47.6X1	T47.6X2	T47.6X3	T47.6X4	T47.6X5	T47.6X6
alpha-adrenoreceptor	T44.6X1	T44.6X2	T44.6X3	T44.6X4	T44.6X5	T44.6X6	absorbent	T47.6X1	T47.6X2	T47.6X3	T47.6X4	T47.6X5	T47.6X6
anticoagulant	T45.7X1	T45.7X2	T45.7X3	T45.7X4	T45.7X5	T45.7X6	Anti-D immunoglobulin (human)	T50.211	T50.212	T50.213	T50.214	T50.215	T50.216
beta-adrenoreceptor	T44.7X1	T44.7X2	T44.7X3	T44.7X4	T44.7X5	T44.7X6	Antidiphtheria serum	T38.891	T38.892	T38.893	T38.894	T38.895	T38.896
extrapyramidal NEC	T44.3X1	T44.3X2	T44.3X3	T44.3X4	T44.3X5	T44.3X6	Antidiuretic hormone	T50.6X1	T50.6X2	T50.6X3	T50.6X4	T50.6X5	T50.6X6
folic acid	T45.1X1	T45.1X2	T45.1X3	T45.1X4	T45.1X5	T45.1X6	Antidote NEC	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6
H2 receptor	T47.0X1	T47.0X2	T47.0X3	T47.0X4	T47.0X5	T47.0X6	heavy metal	T46.2X1	T46.2X2	T46.2X3	T46.2X4	T46.2X5	T46.2X6
heavy metal	T45.8X1	T45.8X2	T45.8X3	T45.8X4	T45.8X5	T45.8X6	Antidysrhythmic NEC						
narcotic analgesic	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6							
opiate	T50.7X1	T50.7X2	T50.7X3	T50.7X4	T50.7X5	T50.7X6							
pyrimidine	T45.1X1	T45.1X2											

Chapter 2. Neoplasms (C00–D49)

Chapter-specific Guidelines with Coding Examples

The chapter-specific guidelines from the ICD-10-CM Official Guidelines for Coding and Reporting have been provided below. Along with these guidelines are coding examples, contained in the shaded boxes, that have been developed to help illustrate the coding and/or sequencing guidance found in these guidelines.

General guidelines

Chapter 2 of the ICD-10-CM contains the codes for most benign and all malignant neoplasms. Certain benign neoplasms, such as prostatic adenomas, may be found in the specific body system chapters. To properly code a neoplasm, it is necessary to determine from the record if the neoplasm is benign, in-situ, malignant, or of uncertain histologic behavior. If malignant, any secondary (metastatic) sites should also be determined.

Primary malignant neoplasms overlapping site boundaries

A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous such as tumors in different quadrants of the same breast, codes for each site should be assigned.

A 73-year-old white female with a large rapidly growing malignant tumor in the left breast extending from the upper outer quadrant into the axillary tail

C50.812 Malignant neoplasm of overlapping sites of left female breast

Explanation: Because this is a single large tumor that overlaps two contiguous sites, a single code for overlapping sites is assigned.

A 52-year old white female with two distinct lesions of the right breast, one (0.5 cm) in the upper outer quadrant and a second (1.5 cm) in the lower outer quadrant; path report indicates both lesions are malignant

C50.411 Malignant neoplasm of upper-outer quadrant of right female breast

C50.511 Malignant neoplasm of lower-outer quadrant of right female breast

Explanation: This patient has two distinct malignant lesions of right breast in adjacent quadrants. Because the lesions are not contiguous, two codes are reported.

Malignant neoplasm of ectopic tissue

Malignant neoplasms of ectopic tissue are to be coded to the site of origin mentioned, e.g., ectopic pancreatic malignant neoplasms involving the stomach are coded to malignant neoplasm of pancreas, unspecified (C25.9).

The neoplasm table in the Alphabetic Index should be referenced first. However, if the histological term is documented, that term should be referenced first, rather than going immediately to the Neoplasm Table, in order to determine which column in the Neoplasm Table is appropriate. For example, if the documentation indicates "adenoma," refer to the term in the Alphabetic Index to review the entries under this term and the instructional note to "see also neoplasm, by site, benign." The table provides the proper code based on the type of neoplasm and the site. It is important to select the proper column in the table that corresponds to the type of neoplasm. The Tabular List should then be referenced to verify that the correct code has been selected from the table and that a more specific site code does not exist.

See Section I.C.21. Factors influencing health status and contact with health services, Status, for information regarding Z15.0, codes for genetic susceptibility to cancer.

a. Admission/Encounter for treatment of primary site

If the malignancy is chiefly responsible for occasioning the patient admission/encounter and treatment is directed at the primary site, designate the primary malignancy as the principal/first-listed diagnosis.

The only exception to this guideline is if the administration of chemotherapy, immunotherapy or external beam radiation therapy is chiefly responsible for occasioning the admission/encounter. In that case, assign the appropriate Z51.-- code as the first-listed or principal diagnosis, and the underlying diagnosis or problem for which the service is being performed as a secondary diagnosis.

b. Admission/Encounter for treatment of secondary site

When a patient is admitted because of a primary neoplasm with metastasis and treatment is directed toward the secondary site only, the secondary

neoplasm is designated as the principal diagnosis even though the primary malignancy is still present.

Patient with primary prostate cancer with metastasis to lungs admitted for wedge resection of mass in right lung

C78.01 Secondary malignant neoplasm of right lung

C61 Malignant neoplasm of prostate

Explanation: Since the admission is for treatment of the lung metastasis, the secondary lung metastasis is sequenced before the primary prostate cancer.

c. Coding and sequencing of complications

Coding and sequencing of complications associated with the malignancies or with the therapy thereof are subject to the following guidelines:

1) Anemia associated with malignancy

When admission/encounter is for management of an anemia associated with the malignancy, and the treatment is only for anemia, the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis followed by the appropriate code for the anemia (such as code D63.0, Anemia in neoplastic disease).

Patient is admitted for treatment of anemia in advanced colon cancer

C18.9 Malignant neoplasm of colon, unspecified

D63.0 Anemia in neoplastic disease

Explanation: Even though the admission was solely to treat the anemia, this guideline indicates that the code for the malignancy is sequenced first.

2) Anemia associated with chemotherapy, immunotherapy and radiation therapy

When the admission/encounter is for management of an anemia associated with an adverse effect of the administration of chemotherapy or immunotherapy and the only treatment is for the anemia, the anemia code is sequenced first followed by the appropriate codes for the neoplasm and the adverse effect (T45.1X5, Adverse effect of antineoplastic and immunosuppressive drugs).

A 56-year-old Hispanic male with grade II follicular lymphoma involving multiple lymph node sites referred for blood transfusion to treat anemia due to chemotherapy

D64.81 Anemia due to antineoplastic chemotherapy

C82.18 Follicular lymphoma grade II, lymph nodes of multiple sites

T45.1X5A Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter

Explanation: The code for the anemia is sequenced first followed by the code for the malignant neoplasm and lastly the code for the adverse effect.

When the admission/encounter is for management of an anemia associated with an adverse effect of radiotherapy, the anemia code should be sequenced first, followed by the appropriate neoplasm code and code Y84.2, Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure.

A 55-year-old male with a large malignant rectal tumor has been receiving external radiation therapy to shrink the tumor prior to planned surgery. He is admitted today for a blood transfusion to treat anemia related to radiation therapy.

D64.89 Other specified anemias

C20 Malignant neoplasm of rectum

Y84.2 Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

Explanation: The code for the anemia is sequenced first, followed by the code for the malignancy, and lastly the code for the abnormal reaction due to radiotherapy.

✓4th **I72 Other aneurysm**

- INCLUDES** aneurysm (cirroid) (false) (ruptured)
EXCLUDES 2 acquired aneurysm (I77.0)
 aneurysm (of) aorta (I71.-)
 aneurysm (of) arteriovenous NOS (Q27.3-)
 carotid artery dissection (I77.71)
 cerebral (nonruptured) aneurysm (I67.1)
 coronary aneurysm (I25.4)
 coronary artery dissection (I25.42)
 dissection of artery NEC (I77.79)
 dissection of precerebral artery, congenital (nonruptured) (Q28.1)
 heart aneurysm (I25.3)
 iliac artery dissection (I77.72)
 precerebral artery, congenital (nonruptured) (Q28.1)
 pulmonary artery aneurysm (I28.1)
 renal artery dissection (I77.73)
 retinal aneurysm (H35.0)
 ruptured cerebral aneurysm (I60.7)
 varicose aneurysm (I77.0)
 vertebral artery dissection (I77.74)

AHA: 2016,4Q,28-29

I72.0 Aneurysm of carotid artery

- Aneurysm of common carotid artery
 Aneurysm of external carotid artery
 Aneurysm of internal carotid artery, extracranial portion
EXCLUDES 1 aneurysm of internal carotid artery, intracranial portion (I67.1)
 aneurysm of internal carotid artery NOS (I67.1)

I72.1 Aneurysm of artery of upper extremity

I72.2 Aneurysm of renal artery

I72.3 Aneurysm of iliac artery

I72.4 Aneurysm of artery of lower extremity

AHA: 2019,2Q,21

I72.5 Aneurysm of other precerebral arteries

- Aneurysm of basilar artery (trunk)
EXCLUDES 2 aneurysm of carotid artery (I72.0)
 aneurysm of vertebral artery (I72.6)
 dissection of carotid artery (I77.71)
 dissection of other precerebral arteries (I77.75)
 dissection of vertebral artery (I77.74)


I72.6 Aneurysm of vertebral artery

- EXCLUDES 2** dissection of vertebral artery (I77.74)

I72.8 Aneurysm of other specified arteries

I72.9 Aneurysm of unspecified site

Aneurysm



✓4th **I73 Other peripheral vascular diseases**

- EXCLUDES 2** chilblains (T69.1)
 frostbite (T33-T34)
 immersion hand or foot (T69.0-)
 spasm of cerebral artery (G45.9)

AHA: 2018,4Q,87

✓5th **I73.0 Raynaud's syndrome**

- Raynaud's disease
 Raynaud's phenomenon (secondary)
DEF: Constriction of the arteries of the digits caused by cold or by nerve or arterial damage and can be prompted by stress or emotion. Blood cannot reach the skin and soft tissues and the skin turns white with blue mottling.

I73.00 Raynaud's syndrome without gangrene

I73.01 Raynaud's syndrome with gangrene CC HCC

I73.1 Thromboangiitis obliterans [Buerger's disease]

- DEF:** Inflammatory disease of the extremity blood vessels, mainly the lower blood vessels. This disease is associated with heavy tobacco use. The arteries are more affected than veins. It occurs primarily in young men and leads to tissue ischemia and gangrene.

✓5th **I73.8 Other specified peripheral vascular diseases**

- EXCLUDES 1** diabetic (peripheral) angiopathy (E08-E13 with .51-.52)

I73.81 Erythromelalgia

I73.89 Other specified peripheral vascular diseases

- Acrocyanosis
 Erythrocyanosis
 Simple acroparesthesia [Schultze's type]
 Vasomotor acroparesthesia [Nothnagel's type]

I73.9 Peripheral vascular disease, unspecified

- Intermittent claudication
 Peripheral angiopathy NOS
 Spasm of artery
EXCLUDES 1 atherosclerosis of the extremities (I70.2-I70.7)

AHA: 2018,2Q,7

✓4th **I74 Arterial embolism and thrombosis**

- INCLUDES** embolic infarction
 embolic occlusion
 thrombotic infarction
 thrombotic occlusion

Code first:

- embolism and thrombosis complicating abortion or ectopic or molar pregnancy (O00-O07, O08.2)
 embolism and thrombosis complicating pregnancy, childbirth and the puerperium (O88.-)

EXCLUDES 2 atheroembolism (I75.-)

- basilar embolism and thrombosis (I63.0-I63.2, I65.1)
 carotid embolism and thrombosis (I63.0-I63.2, I65.2)
 cerebral embolism and thrombosis (I63.3-I63.5, I66.-)
 coronary embolism and thrombosis (I21-I25)
 mesenteric embolism and thrombosis (K55.0-)
 ophthalmic embolism and thrombosis (H34.-)
 precerebral embolism and thrombosis NOS (I63.0-I63.2, I65.9)
 pulmonary embolism and thrombosis (I26.-)
 renal embolism and thrombosis (N28.0)
 retinal embolism and thrombosis (H34.-)
 septic embolism and thrombosis (I76)
 vertebral embolism and thrombosis (I63.0-I63.2, I65.0)

AHA: 2023,2Q,7

✓5th **I74.0 Embolism and thrombosis of abdominal aorta**

I74.01 Saddle embolus of abdominal aorta MCC HCC

I74.09 Other arterial embolism and thrombosis of abdominal aorta CC HCC

- Aortic bifurcation syndrome
 Aortoiliac obstruction
 Leriche's syndrome

✓5th **I74.1 Embolism and thrombosis of other and unspecified parts of aorta**

I74.10 Embolism and thrombosis of unspecified parts of aorta CC HCC

I74.11 Embolism and thrombosis of thoracic aorta CC HCC

I74.19 Embolism and thrombosis of other parts of aorta CC HCC

I74.2 Embolism and thrombosis of arteries of the upper extremities CC HCC

I74.3 Embolism and thrombosis of arteries of the lower extremities CC HCC

I74.4 Embolism and thrombosis of arteries of extremities, unspecified CC HCC

- Peripheral arterial embolism NOS

I74.5 Embolism and thrombosis of iliac artery CC HCC

I74.8 Embolism and thrombosis of other arteries CC HCC

I74.9 Embolism and thrombosis of unspecified artery CC HCC

✓4th **I75 Atheroembolism**

- INCLUDES** atherothrombotic microembolism
 cholesterol embolism

✓5th **I75.0 Atheroembolism of extremities**

✓5th **I75.01 Atheroembolism of upper extremity**

I75.011 Atheroembolism of right upper extremity CC HCC

N07.5 Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis CC

Hereditary nephropathy, not elsewhere classified with membranoproliferative glomerulonephritis, types 1 and 3, or NOS

EXCLUDES 1 hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis (N07.A)
hereditary nephropathy, not elsewhere classified with C3 glomerulopathy (N07.A)

N07.6 Hereditary nephropathy, not elsewhere classified with dense deposit disease

Hereditary nephropathy, not elsewhere classified with C3 glomerulopathy with dense deposit disease
Hereditary nephropathy, not elsewhere classified with membranoproliferative glomerulonephritis, type 2

N07.7 Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis

Hereditary nephropathy, not elsewhere classified with extracapillary glomerulonephritis

N07.8 Hereditary nephropathy, not elsewhere classified with other morphologic lesions

Hereditary nephropathy, not elsewhere classified with proliferative glomerulonephritis NOS

N07.9 Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions

N07.A Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis CC

Hereditary nephropathy, not elsewhere classified with C3 glomerulopathy

EXCLUDES 1 hereditary nephropathy, not elsewhere classified (with C3 glomerulopathy) with dense deposit disease (N07.6)

N08 Glomerular disorders in diseases classified elsewhere

Glomerulonephritis
Nephritis
Nephropathy

Code first underlying disease, such as:

- amyloidosis (E85.-)
- congenital syphilis (A50.5)
- cryoglobulinemia (D89.1)
- disseminated intravascular coagulation (D65)
- gout (M1A.-, M10.-)
- microscopic polyangiitis (M31.7)
- multiple myeloma (C90.0-)
- sepsis (A40.0-A41.9)
- sickle-cell disease (D57.0-D57.8)

EXCLUDES 1 glomerulonephritis, nephritis and nephropathy (in):
antiglomerular basement membrane disease (M31.0)
diabetes (E08-E13 with .21)
gonococcal (A54.21)
Goodpasture's syndrome (M31.0)
hemolytic-uremic syndrome (D59.3-)
lupus (M32.14)
mumps (B26.83)
syphilis (A52.75)
systemic lupus erythematosus (M32.14)
Wegener's granulomatosis (M31.31)
pyelonephritis in diseases classified elsewhere (N16)
renal tubulo-interstitial disorders classified elsewhere (N16)

Renal tubulo-interstitial diseases (N10-N16)

INCLUDES pyelonephritis

EXCLUDES 1 pyeloureteritis cystica (N28.85)

N10 Acute pyelonephritis CC H6

Acute infectious interstitial nephritis
Acute pyelitis
Acute tubulo-interstitial nephritis
Hemoglobin nephrosis
Myoglobin nephrosis

Use additional code (B95-B97), to identify infectious agent

AHA: 2020,3Q,25; 2019,3Q,13

N11 Chronic tubulo-interstitial nephritis

INCLUDES chronic infectious interstitial nephritis
chronic pyelitis
chronic pyelonephritis

Use additional code (B95-B97), to identify infectious agent

N11.0 Nonobstructive reflux-associated chronic pyelonephritis

Pyelonephritis (chronic) associated with (vesicoureteral) reflux

EXCLUDES 1 vesicoureteral reflux NOS (N13.70)

N11.1 Chronic obstructive pyelonephritis CC

Pyelonephritis (chronic) associated with anomaly of pelviureteric junction
Pyelonephritis (chronic) associated with anomaly of pyeloureteric junction
Pyelonephritis (chronic) associated with crossing of vessel
Pyelonephritis (chronic) associated with kinking of ureter
Pyelonephritis (chronic) associated with obstruction of ureter
Pyelonephritis (chronic) associated with stricture of pelviureteric junction
Pyelonephritis (chronic) associated with stricture of ureter

EXCLUDES 1 calculous pyelonephritis (N20.9)
obstructive uropathy (N13.-)

N11.8 Other chronic tubulo-interstitial nephritis CC

Nonobstructive chronic pyelonephritis NOS

N11.9 Chronic tubulo-interstitial nephritis, unspecified CC H6

Chronic interstitial nephritis NOS
Chronic pyelitis NOS
Chronic pyelonephritis NOS

N12 Tubulo-interstitial nephritis, not specified as acute or chronic CC H6

Interstitial nephritis NOS
Pyelitis NOS
Pyelonephritis NOS

EXCLUDES 1 calculous pyelonephritis (N20.9)

N13 Obstructive and reflux uropathy

EXCLUDES 2 calculus of kidney and ureter without hydronephrosis (N20.-)
congenital obstructive defects of renal pelvis and ureter (Q62.0-Q62.3)

hydronephrosis with ureteropelvic junction obstruction (Q62.11)
obstructive pyelonephritis (N11.1)

DEF: Hydronephrosis: Distension of the kidney caused by an accumulation of urine that cannot flow out due to an obstruction that may be caused by conditions such as kidney stones or vesicoureteral reflux.


N13.0 Hydronephrosis with ureteropelvic junction obstruction CC

Hydronephrosis due to acquired occlusion of ureteropelvic junction

EXCLUDES 2 hydronephrosis with ureteropelvic junction obstruction due to calculus (N13.2)

AHA: 2016,4Q,43

Hydronephrosis/UPJ Obstruction



- Q18.2 Other branchial cleft malformations** PE
 Branchial cleft malformation NOS
 Cervical auricle
 Otocephaly
- Q18.3 Webbing of neck** PE
 Pterygium colli
DEF: Congenital malformation characterized by a thick, triangular skinfold that stretches from the lateral side of the neck across the shoulder. It is associated with genetic conditions such as Turner's and Noonan's syndromes.
- Q18.4 Macrostomia** PE
DEF: Rare congenital craniofacial bilateral or unilateral anomaly of the mouth due to malformed maxillary and mandibular processes. It results in an abnormally large mouth extending toward the ear.
- Q18.5 Microstomia** PE
- Q18.6 Macrocheilia** PE
 Hypertrophy of lip, congenital
- Q18.7 Microcheilia** PE
- Q18.8 Other specified congenital malformations of face and neck** PE
 Medial cyst of face and neck
 Medial fistula of face and neck
 Medial sinus of face and neck
- Q18.9 Congenital malformation of face and neck, unspecified** PE
 Congenital anomaly NOS of face and neck


Congenital malformations of the circulatory system (Q20–Q28)

- Q20 Congenital malformations of cardiac chambers and connections** PE
EXCLUDES1 dextrocardia with situs inversus (Q89.3)
 mirror-image atrial arrangement with situs inversus (Q89.3)
- Q20.0 Common arterial trunk** MCC PE
 Persistent truncus arteriosus
EXCLUDES1 aortic septal defect (Q21.4)
- Q20.1 Double outlet right ventricle** MCC PE
 Taussig-Bing syndrome
- Q20.2 Double outlet left ventricle** MCC PE
- Q20.3 Discordant ventriculoarterial connection** MCC PE
 Dextrotransposition of aorta
 Transposition of great vessels (complete)
- Q20.4 Double inlet ventricle** MCC PE
 Common ventricle
 Cor triloculare batriatum
 Single ventricle
- Q20.5 Discordant atrioventricular connection** CC PE
 Corrected transposition
 Levotransposition
 Ventricular inversion
- Q20.6 Isomerism of atrial appendages** PE
 Isomerism of atrial appendages with asplenia or polysplenia
- Q20.8 Other congenital malformations of cardiac chambers and connections** PE
 Cor binoculare
- Q20.9 Congenital malformation of cardiac chambers and connections, unspecified** PE

Q21 Congenital malformations of cardiac septa

EXCLUDES1 acquired cardiac septal defect (I51.0)


- Q21.0 Ventricular septal defect** CC PE
 Roger's disease



Q21.1 Atrial septal defect

EXCLUDES2 ostium primum atrial septal defect (type I) (Q21.20)
AHA: 2022,4Q,39-40

Atrial Septal Defect




- Q21.10 Atrial septal defect, unspecified** CC PE
- Q21.11 Secundum atrial septal defect** CC PE
 Fenestrated atrial septum
 Patent or persistent ostium secundum defect (type II)
- Q21.12 Patent foramen ovale** CC PE
 Persistent foramen ovale
- Q21.13 Coronary sinus atrial septal defect** CC PE
 Coronary sinus defect
 Unroofed coronary sinus
- Q21.14 Superior sinus venosus atrial septal defect** CC PE
 Superior vena cava type atrial septal defect
- Q21.15 Inferior sinus venosus atrial septal defect** CC PE
 Inferior vena cava type atrial septal defect
- Q21.16 Sinus venosus atrial septal defect, unspecified** CC PE
 Sinus venosus defect, NOS
- Q21.19 Other specified atrial septal defect** CC PE
 Common atrium
 Other specified atrial septal abnormality

- ✓7th T80.419 Rh incompatibility with hemolytic transfusion reaction, unspecified** **CC PE**
Rh incompatibility with hemolytic transfusion reaction at unspecified time after transfusion
Hemolytic transfusion reaction (HTR) due to Rh incompatibility NOS
- ✓x7th T80.49 Other Rh incompatibility reaction due to transfusion of blood or blood products** **CC PE**
Delayed serologic transfusion reaction (DSTR) from Rh incompatibility
Other reaction to Rh incompatible blood transfusion
- ✓5th T80.A Non-ABO incompatibility reaction due to transfusion of blood or blood products**
Reaction due to incompatibility of minor antigens (Duffy) (Kell) (Kidd) (Lewis) (M) (N) (P) (S)
- ✓x7th T80.A0 Non-ABO incompatibility reaction due to transfusion of blood or blood products, unspecified** **CC PE**
Non-ABO antigen incompatibility reaction from transfusion NOS
- ✓6th T80.A1 Non-ABO incompatibility with hemolytic transfusion reaction**
- ✓7th T80.A10 Non-ABO incompatibility with acute hemolytic transfusion reaction** **CC PE**
Acute hemolytic transfusion reaction (AHTR) due to non-ABO incompatibility
Non-ABO incompatibility with hemolytic transfusion reaction less than 24 hours after transfusion
- ✓7th T80.A11 Non-ABO incompatibility with delayed hemolytic transfusion reaction** **CC PE**
Delayed hemolytic transfusion reaction (DHTR) due to non-ABO incompatibility
Non-ABO incompatibility with hemolytic transfusion reaction 24 or more hours after transfusion
- ✓7th T80.A19 Non-ABO incompatibility with hemolytic transfusion reaction, unspecified** **CC PE**
Hemolytic transfusion reaction (HTR) due to non-ABO incompatibility NOS
Non-ABO incompatibility with hemolytic transfusion reaction at unspecified time after transfusion
- ✓x7th T80.A9 Other non-ABO incompatibility reaction due to transfusion of blood or blood products** **CC PE**
Delayed serologic transfusion reaction (DSTR) from non-ABO incompatibility
Other reaction to non-ABO incompatible blood transfusion
- ✓5th T80.5 Anaphylactic reaction due to serum**
Allergic shock due to serum
Anaphylactic shock due to serum
Anaphylactoid reaction due to serum
Anaphylaxis due to serum
EXCLUDES 1 ABO incompatibility reaction due to transfusion of blood or blood products (T80.3-) allergic reaction or shock NOS (T78.2) anaphylactic reaction or shock NOS (T78.2) anaphylactic reaction or shock due to adverse effect of correct medicinal substance properly administered (T88.6) other serum reaction (T80.6-)
DEF: Life-threatening hypersensitivity to a foreign serum causing respiratory distress, vascular collapse, and shock.
- ✓x7th T80.51 Anaphylactic reaction due to administration of blood and blood products** **CC PE**
- ✓x7th T80.52 Anaphylactic reaction due to vaccination** **CC PE**
AHA: 2021,1Q,43
- ✓x7th T80.59 Anaphylactic reaction due to other serum** **CC PE**
- ✓5th T80.6 Other serum reactions**
Intoxication by serum
Protein sickness
Serum rash
Serum sickness
Serum urticaria
EXCLUDES 2 serum hepatitis (B16-B19)
DEF: Serum sickness: Hypersensitivity to a foreign serum that causes fever, hives, swelling, and lymphadenopathy.
- ✓x7th T80.61 Other serum reaction due to administration of blood and blood products** **CC PE**
- ✓x7th T80.62 Other serum reaction due to vaccination** **CC PE**
AHA: 2021,1Q,42
- ✓x7th T80.69 Other serum reaction due to other serum** **CC PE**
Code also, if applicable, arthropathy in hypersensitivity reactions classified elsewhere (M36.4)
- ✓5th T80.8 Other complications following infusion, transfusion and therapeutic injection**
- ✓6th T80.81 Extravasation of vesicant agent**
Infiltration of vesicant agent
- ✓7th T80.810 Extravasation of vesicant antineoplastic chemotherapy** **CC PE**
Infiltration of vesicant antineoplastic chemotherapy
- ✓7th T80.818 Extravasation of other vesicant agent** **CC PE**
Infiltration of other vesicant agent
- ✓x7th T80.82 Complication of immune effector cellular therapy** **PE**
Complication of chimeric antigen receptor (CAR-T) cell therapy
Complication of IEC therapy
Use additional code to identify the specific complication, such as:
cytokine release syndrome (D89.83-)
immune effector cell-associated neurotoxicity syndrome (G92.0-)
EXCLUDES 2 ▶ adverse effect of immune checkpoint inhibitors and immunostimulant drugs (T45.AX5) ◀
complication of bone marrow transplant (T86.0)
complication of stem cell transplant (T86.5)
AHA: 2021,4Q,31
- ✓x7th T80.89 Other complications following infusion, transfusion and therapeutic injection** **PE**
Delayed serologic transfusion reaction (DSTR), unspecified incompatibility
Use additional code to identify graft-versus-host reaction, if applicable, (D89.81-)
AHA: 2020,4Q,14
- ✓5th T80.9 Unspecified complication following infusion, transfusion and therapeutic injection**
- ✓x7th T80.90 Unspecified complication following infusion and therapeutic injection** **PE**
- ✓6th T80.91 Hemolytic transfusion reaction, unspecified incompatibility** **EXCLUDES 1** ABO incompatibility with hemolytic transfusion reaction (T80.31-) non-ABO incompatibility with hemolytic transfusion reaction (T80.A1-) Rh incompatibility with hemolytic transfusion reaction (T80.41-)
- ✓7th T80.910 Acute hemolytic transfusion reaction, unspecified incompatibility** **CC PE**
- ✓7th T80.911 Delayed hemolytic transfusion reaction, unspecified incompatibility** **CC PE**
- ✓7th T80.919 Hemolytic transfusion reaction, unspecified incompatibility, unspecified as acute or delayed** **CC PE**
Hemolytic transfusion reaction NOS
- ✓x7th T80.92 Unspecified transfusion reaction** **PE**
Transfusion reaction NOS

Chapter 9. Diseases of the Circulatory System (I00–I99)

Anatomy of the Heart



Heart Cross Section

